PFIZER INC Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
PFIZER INC (PFE) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $2.70 billion for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-04
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-28 was $2.70B, a 18.65% increase year-over-year.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-03-29 was $2.34B, a 10.70% increase year-over-year.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $2.58B, a 14.86% increase year-over-year.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-28 was $2.30B, a 20.95% increase year-over-year.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $9.27B, a 10.47% increase from fiscal 2024.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $8.39B, a 10.63% increase from fiscal 2023.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $7.58B, a 11.19% decline from fiscal 2022.
- PFIZER INC revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $8.54B, a 11.57% increase from fiscal 2021.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-28 | $2.70B 10-Q · filed 2026-08-04 | $5.04B 10-Q · filed 2026-08-04 | $7.62B derived: sum of 3 quarters · filed 2026-08-04 | $9.92B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-29 | $2.34B 10-Q · filed 2026-05-05 | $4.92B derived: sum of 2 quarters · filed 2026-05-05 | $7.22B derived: sum of 3 quarters · filed 2026-05-05 | $9.49B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.58B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.88B derived: sum of 2 quarters · filed 2026-02-26 | $7.15B derived: sum of 3 quarters · filed 2026-08-04 | $9.27B 10-K · filed 2026-02-26 |
| 2025-09-28 | $2.30B 10-Q · filed 2025-11-04 | $4.57B derived: sum of 2 quarters · filed 2026-08-04 | $6.68B 10-Q · filed 2025-11-04 | $8.93B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-29 | $2.27B 10-Q · filed 2026-08-04 | $4.39B 10-Q · filed 2026-08-04 | $6.63B derived: sum of 3 quarters · filed 2026-08-04 | $8.53B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-30 | $2.11B 10-Q · filed 2026-05-05 | $4.36B derived: sum of 2 quarters · filed 2026-05-05 | $6.26B derived: sum of 3 quarters · filed 2026-05-05 | $8.33B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.25B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.15B derived: sum of 2 quarters · filed 2026-02-26 | $6.21B derived: sum of 3 quarters · filed 2026-02-26 | $8.39B 10-K · filed 2026-02-26 |
| 2024-09-29 | $1.90B 10-Q · filed 2025-11-04 | $3.97B derived: sum of 2 quarters · filed 2025-11-04 | $6.14B 10-Q · filed 2025-11-04 | $8.05B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.07B 10-Q · filed 2025-08-05 | $4.24B 10-Q · filed 2025-08-05 | $6.15B derived: sum of 3 quarters · filed 2026-02-26 | $7.79B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.17B 10-Q · filed 2025-05-05 | $4.08B derived: sum of 2 quarters · filed 2026-02-26 | $5.73B derived: sum of 3 quarters · filed 2026-02-26 | $7.69B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.91B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.56B derived: sum of 2 quarters · filed 2026-02-26 | $5.52B derived: sum of 3 quarters · filed 2026-02-26 | $7.58B 10-K · filed 2026-02-26 |
| 2023-10-01 | $1.65B 10-Q · filed 2024-11-04 | $3.61B derived: sum of 2 quarters · filed 2024-11-04 | $5.67B 10-Q · filed 2024-11-04 | |
| 2023-07-02 | $1.97B 10-Q · filed 2024-08-05 | $4.03B 10-Q · filed 2024-08-05 | ||
| 2023-04-02 | $2.06B 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $8.54B 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $7.65B 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |